225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Clinical trial NCT06287944 · RECRUITING
Trial details
- NCT number
- NCT06287944
- Sponsor
- City of Hope Medical Center
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2028-05-19
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.